Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Riccardo De Robertis Lombardi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0930-4337; OpenAlex author ID A5000836077. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
50
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 3 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers

Papers 19

  1. Conspicuity and characterization of pre-selected hypodense hepatic lesions in pancreatic cancer patients: limited clinical value of dual-energy portal phase CT. Co-author DOI 10.1007/s00261-026-05802-9↗
  2. Can Machine Learning Predict Metastatic Sites in Pancreatic Ductal Adenocarcinoma? A Radiomic Analysis. First author DOI 10.1007/s10278-025-01627-y↗
  3. CT texture analysis and delta radiomics in predicting R0 resection after preoperative chemotherapy in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2026.102900↗
  4. Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characte… Co-author DOI 10.1002/path.6437↗
  5. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial. Co-author DOI 10.1016/j.ejca.2023.113430↗
  6. Liver metastases in pancreatic ductal adenocarcinoma: a predictive model based on CT texture analysis. Co-author DOI 10.1007/s11547-022-01548-8↗
  7. US-Guided Percutaneous Radiofrequency Ablation of Locally Advanced Pancreatic Adenocarcinoma: A 5-Year High-Volume Center Experience. Co-author DOI 10.1055/a-1178-0474↗
  8. Correlation between ADC Histogram-Derived Metrics and the Time to Metastases in Resectable Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers14246050↗
  9. Correlation of MR features and histogram-derived parameters with aggressiveness and outcomes after resection in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00261-020-02509-3↗
  10. Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to … Co-author DOI 10.3389/fonc.2020.600940↗
  11. Preoperative Imaging Evaluation after Downstaging of Pancreatic Ductal Adenocarcinoma: A Multi-Center Study. Co-author DOI 10.3390/cancers11020267↗
  12. Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results. Co-author DOI 10.1016/j.pan.2018.04.002↗
  13. Palliative therapy in pancreatic cancer-interventional treatment with radiofrequency ablation/irreversible electroporation. Co-author DOI 10.21037/tgh.2018.10.05↗
  14. Percutaneous Radiofrequency Ablation of Unresectable Locally Advanced Pancreatic Cancer: Preliminary Results. Co-author DOI 10.1177/1533034616649292↗
  15. The borderline resectable/locally advanced pancreatic ductal adenocarcinoma staging with computed tomography/magnetic resonance imaging. Co-author DOI 10.4103/eus.eus_67_17↗
  16. Percutaneous ablation of pancreatic cancer. Co-author DOI 10.3748/wjg.v22.i44.9661↗
  17. Variation of tumoral marker after radiofrequency ablation of pancreatic adenocarcinoma. Co-author DOI 10.3978/j.issn.2078-6891.2015.085↗
  18. Diffusion-weighted imaging of pancreatic cancer. Co-author DOI 10.4329/wjr.v7.i10.319↗
  19. Comparison between CT and CEUS in the diagnosis of pancreatic adenocarcinoma. Co-author DOI 10.1055/s-0032-1325324↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mirko D’Onofrio · 17 shared papers, 2013–2026 · strength 2.38
  2. Roberto Salvia · 12 shared papers, 2016–2025 · strength 1.19
  3. Giuseppe Malleo · 7 shared papers, 2018–2026 · strength 1.10
  4. Claudio Bassi · 10 shared papers, 2016–2024 · strength 0.86
  5. Salvatore Paiella · 8 shared papers, 2016–2022 · strength 0.63
  6. Davide Melisi · 4 shared papers, 2018–2026 · strength 0.61
  7. Flavio Spoto · 2 shared papers, 2026 · strength 0.60
  8. Alessandro Beleù · 4 shared papers, 2019–2022 · strength 0.51
  9. Aldo Scarpa Scarpa · 4 shared papers, 2018–2025 · strength 0.45
  10. Simona Casalino · 2 shared papers, 2024–2026 · strength 0.44
  11. Michèle Milella · 2 shared papers, 2020–2026 · strength 0.41
  12. Giovanni Butturini · 4 shared papers, 2016–2024 · strength 0.33
  13. Roberto Girelli · 4 shared papers, 2016–2022 · strength 0.32
  14. Isabella M. Frigerio · 3 shared papers, 2016–2022 · strength 0.31
  15. Claudio Luchini · 2 shared papers, 2024–2025 · strength 0.31
  16. Giovanni Marchegiani · 3 shared papers, 2018–2024 · strength 0.29
  17. Stefano Francesco Crinò · 2 shared papers, 2018–2024 · strength 0.23
  18. Alessandro Esposito · 2 shared papers, 2018–2024 · strength 0.21
  19. Francesca Masetto · 1 shared paper, 2025 · strength 0.16
  20. Jaswinder Singh Samra · 1 shared paper, 2025 · strength 0.16
  21. Αναστάσιος Γκουντάκος · 1 shared paper, 2025 · strength 0.16
  22. Antonio Pea · 1 shared paper, 2025 · strength 0.16
  23. Kohei Fujikura · 1 shared paper, 2025 · strength 0.16
  24. Michele Simbolo · 1 shared paper, 2025 · strength 0.16
  25. Amber L. Johns · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.